查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1613242

皮膚 T 細胞淋巴瘤市場：按適應症、治療、產品和最終用戶分類 - 全球預測 2025-2030

Cutaneous T-Cell-Lymphoma Market (CTCL) by Indication (Mycosis Fungoides, Sezary Syndrome), Treatment (Biological Therapies, Phototherapy, Radiation Therapy), Product, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年皮膚T細胞淋巴瘤市值為4.1677億美元，預計到2024年將達到4.3244億美元，複合年成長率為3.91%，預計到2030年將達到5.4549億美元。

皮膚 T 細胞淋巴瘤 (CTCL) 是一種罕見的非何傑金氏淋巴瘤，主要影響皮膚，其特徵是 T 細胞增殖不受控制。 CTCL 有多種形式，其中最常見的是蕈狀肉芽腫和塞札裡症候群。研究這個市場的必要性源自於 CTCL 的複雜生物學性質，這需要創新的診斷和治療方法。這項研究將有助於開發新的治療方法、改善診斷並幫助醫療保健提供者最佳化患者照護。市場洞察的應用擴展到製藥公司、研究機構和臨床環境，以改善治療通訊協定並創建經濟可行的醫療解決方案。最終用途範圍包括醫療機構、實驗室和專注於罕見癌症進展的教育機構。推動市場成長的主要因素是生技藥品、單株抗體的進步以及 CTCL 盛行率的增加。此外，意識的提高和醫療保健基礎設施的改善正在加強市場軌跡。由於該疾病的多樣性，標靶治療和個人化醫療的發展存在重大機遇，利用政府對孤兒藥開發的支持將加速市場開拓。建議包括投資於早期檢測的生物標記研究，以及促進策略合作以開發創新藥物管道。然而，市場成長受到治療成本高和患者數量有限等限制，這可能會減緩投資收益。此外，鑑別診斷的複雜性和抗治療性也是主要問題。克服這些障礙需要專注於精準醫學和適應性臨床試驗設計。創新領域包括利用人工智慧進行預測分析、探索基因治療的潛力以及利用 CTCL 臨床試驗環境中的真實世界證據。這個市場的利基但穩定擴張的性質需要持續的研究和多學科方法來有效解決未滿足的醫療需求。

主要市場統計
基準年[2023] 41677萬美元
預計年份 [2024] 4.3244億美元
預測年份 [2030] 5.4549億美元
複合年成長率（%） 3.91%

市場動態：快速發展的皮膚 T 細胞淋巴瘤市場的關鍵市場洞察

供需的動態交互作用正在改變皮膚 T 細胞淋巴瘤市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 皮膚 T 細胞淋巴瘤的盛行率和認知不斷提高
    • 加速核准流程和獎勵的監管支援政策
  • 市場限制因素
    • 由於誤診和延誤診斷導致治療費用上升
  • 市場機會
    • 擴大臨床試驗和合作研究
    • 擴大標靶治療和免疫療法的發展
  • 市場挑戰
    • 與治療相關的技術和表現問題

波特五力：開拓皮膚 T 細胞淋巴瘤市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解皮膚 T 細胞淋巴瘤市場的外部影響

外部宏觀環境因素在塑造皮膚 T 細胞淋巴瘤市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解皮膚 T 細胞淋巴瘤市場的競爭格局

皮膚 T 細胞淋巴瘤市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位基質皮膚 T 細胞淋巴瘤市場供應商的績效評估

FPNV定位矩陣是評估皮膚T細胞淋巴瘤市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製皮膚 T 細胞淋巴瘤市場的成功之路

皮膚 T 細胞淋巴瘤市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高皮膚 T 細胞淋巴瘤的盛行率和認知
      • 支持快速核准流程和獎勵的監管政策
    • 抑制因素
      • 治療費用上升、誤診和延誤診斷
    • 機會
      • 擴大臨床試驗和合作研究工作
      • 標靶治療和免疫治療的進展
    • 任務
      • 與治療相關的技術和性能問題；
  • 市場區隔分析
    • 適應症：蕈狀肉芽腫病例正快速增加，需要局部和全身性治療。
    • 最終使用者：更多地使用在 CTCL 的特定治療和個人化護理方面提供廣泛專業知識的診所
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按適應症分類的皮膚 T 細胞淋巴瘤市場

  • 蕈狀肉芽腫
  • Sezary症候群

第7章皮膚T細胞淋巴瘤市場（依治療）

  • 生物療法
  • 照光治療
  • 放射治療
  • 局部治療

第 8 章皮膚 T 細胞淋巴瘤市場：依產品

  • 成像技術
  • 分子診斷
  • 照光治療設備
  • 治療藥物
    • 化療
    • 免疫調節劑
    • 標靶治療

第 9 章皮膚 T 細胞淋巴瘤市場：依最終用戶分類

  • 門診手術中心
  • 皮膚科診所
  • 家庭護理設置
  • 醫院
  • 研究中心

第10章美洲皮膚T細胞淋巴瘤市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區皮膚T細胞淋巴瘤市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲皮膚T細胞淋巴瘤市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准創新濾泡性淋巴瘤治療組合
    • FDA核准sokelitinib 作為治療 T 細胞淋巴瘤的孤兒藥
    • 嵌合體 Therapeutics 創新 CTCL 治療獲得 FDA 快速通道認證
  • 戰略分析和建議

公司名單

  • 4SC AG
  • Allos Therapeutics, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Bristol Myers Squibb
  • Corvus Pharmaceuticals, Inc.
  • Eisai Co., Ltd.
  • Elorac, Inc.
  • Helsinn Healthcare SA
  • Incyte Corporation
  • Kyowa Kirin Co., Ltd.
  • Merck & Co. Inc.
  • Mundipharma International Limited
  • PharmaMar SA
  • Seattle Genetics, Inc.
  • Soligenix, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-CB04E05661A6

The Cutaneous T-Cell-Lymphoma Market was valued at USD 416.77 million in 2023, expected to reach USD 432.44 million in 2024, and is projected to grow at a CAGR of 3.91%, to USD 545.49 million by 2030.

Cutaneous T-Cell Lymphoma (CTCL) refers to a rare type of non-Hodgkin's lymphoma that primarily affects the skin, characterized by an uncontrolled proliferation of T-cells. It encompasses various forms, with mycosis fungoides and Sezary syndrome being the most prevalent. The necessity to study this market arises from the complex biological nature of CTCL, which demands innovative diagnostic and treatment approaches. This research informs the development of novel therapies, improved diagnostics, and aids healthcare providers in optimizing patient care. The application of market insights extends to pharmaceutical companies, research institutions, and clinical settings, aiming to refine treatment protocols and create economically viable medical solutions. The end-use scope includes healthcare facilities, research laboratories, and educational institutions focusing on rare cancer advancements. Market growth is primarily driven by advancements in biologics, monoclonal antibodies, and the increasing prevalence of CTCL. Furthermore, rising awareness and improved healthcare infrastructure strengthen the market trajectory. Key opportunities exist in developing targeted therapies and personalized medicine, given the heterogeneity of the disease, and leveraging government support for orphan drug development to accelerate market entry. Recommendations include investing in biomarker research for early detection and pursuing strategic collaborations for innovative therapeutic pipeline development. However, market growth faces limitations like high treatment costs and limited patient populations, which can slow investment returns. Complexity in differential diagnosis and therapeutic resistance also poses significant challenges. Overcoming these hurdles requires a focus on precision medicine and adaptive clinical trial designs. Innovative areas include harnessing AI for predictive analytics, exploring gene therapy prospects, and utilizing real-world evidence in clinical trial settings for CTCL. The nature of this market is niche but steadily expanding, necessitating continuous research and an interdisciplinary approach to address unmet medical needs effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 416.77 million
Estimated Year [2024] USD 432.44 million
Forecast Year [2030] USD 545.49 million
CAGR (%) 3.91%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cutaneous T-Cell-Lymphoma Market

The Cutaneous T-Cell-Lymphoma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence and awareness toward cutaneous t-cell lymphoma
    • Supportive regulatory policies for fast-track approval processes and incentives
  • Market Restraints
    • High cost of treatment, along with misdiagnosis and delayed diagnosis
  • Market Opportunities
    • Expansion of clinical trials and collaborative research initiatives
    • Rising developments in targeted therapies and immunotherapies
  • Market Challenges
    • Technical and performance issues associated with treatments

Porter's Five Forces: A Strategic Tool for Navigating the Cutaneous T-Cell-Lymphoma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cutaneous T-Cell-Lymphoma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cutaneous T-Cell-Lymphoma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cutaneous T-Cell-Lymphoma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cutaneous T-Cell-Lymphoma Market

A detailed market share analysis in the Cutaneous T-Cell-Lymphoma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cutaneous T-Cell-Lymphoma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cutaneous T-Cell-Lymphoma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cutaneous T-Cell-Lymphoma Market

A strategic analysis of the Cutaneous T-Cell-Lymphoma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cutaneous T-Cell-Lymphoma Market, highlighting leading vendors and their innovative profiles. These include 4SC AG, Allos Therapeutics, Inc., Amgen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Bristol Myers Squibb, Corvus Pharmaceuticals, Inc., Eisai Co., Ltd., Elorac, Inc., Helsinn Healthcare SA, Incyte Corporation, Kyowa Kirin Co., Ltd., Merck & Co. Inc., Mundipharma International Limited, PharmaMar SA, Seattle Genetics, Inc., Soligenix, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Cutaneous T-Cell-Lymphoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Mycosis Fungoides and Sezary Syndrome.
  • Based on Treatment, market is studied across Biological Therapies, Phototherapy, Radiation Therapy, and Topical Therapies.
  • Based on Product, market is studied across Imaging Technology, Molecular Diagnostics, Phototherapy Equipment, and Treatment Drugs. The Treatment Drugs is further studied across Chemotherapeutics, Immunomodulators, and Targeted Therapy.
  • Based on End-User, market is studied across Ambulatory Surgery Centers, Dermatology Clinics, Homecare Settings, Hospitals, and Research Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence and awareness toward cutaneous t-cell lymphoma
      • 5.1.1.2. Supportive regulatory policies for fast-track approval processes and incentives
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment, along with misdiagnosis and delayed diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of clinical trials and collaborative research initiatives
      • 5.1.3.2. Rising developments in targeted therapies and immunotherapies
    • 5.1.4. Challenges
      • 5.1.4.1. Technical and performance issues associated with treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication: Burgeoning cases of mycosis fungoides allow for a range of both localized and systemic treatments
    • 5.2.2. End-User: Evolving usage of clinics offering considerable expertise in specific treatments and personalized care for CTCL
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cutaneous T-Cell-Lymphoma Market, by Indication

  • 6.1. Introduction
  • 6.2. Mycosis Fungoides
  • 6.3. Sezary Syndrome

7. Cutaneous T-Cell-Lymphoma Market, by Treatment

  • 7.1. Introduction
  • 7.2. Biological Therapies
  • 7.3. Phototherapy
  • 7.4. Radiation Therapy
  • 7.5. Topical Therapies

8. Cutaneous T-Cell-Lymphoma Market, by Product

  • 8.1. Introduction
  • 8.2. Imaging Technology
  • 8.3. Molecular Diagnostics
  • 8.4. Phototherapy Equipment
  • 8.5. Treatment Drugs
    • 8.5.1. Chemotherapeutics
    • 8.5.2. Immunomodulators
    • 8.5.3. Targeted Therapy

9. Cutaneous T-Cell-Lymphoma Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgery Centers
  • 9.3. Dermatology Clinics
  • 9.4. Homecare Settings
  • 9.5. Hospitals
  • 9.6. Research Centers

10. Americas Cutaneous T-Cell-Lymphoma Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cutaneous T-Cell-Lymphoma Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cutaneous T-Cell-Lymphoma Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Granted Approval of Innovative Follicular Lymphoma Treatment Combination
    • 13.3.2. FDA Endorses Soquelitinib for T-Cell Lymphoma with Orphan Drug Designation
    • 13.3.3. Kymera Therapeutics Granted FDA Fast Track Status for Innovative CTCL Treatment
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4SC AG
  • 2. Allos Therapeutics, Inc.
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. Bausch Health Companies Inc.
  • 6. Bristol Myers Squibb
  • 7. Corvus Pharmaceuticals, Inc.
  • 8. Eisai Co., Ltd.
  • 9. Elorac, Inc.
  • 10. Helsinn Healthcare SA
  • 11. Incyte Corporation
  • 12. Kyowa Kirin Co., Ltd.
  • 13. Merck & Co. Inc.
  • 14. Mundipharma International Limited
  • 15. PharmaMar SA
  • 16. Seattle Genetics, Inc.
  • 17. Soligenix, Inc.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. CUTANEOUS T-CELL-LYMPHOMA MARKET RESEARCH PROCESS
  • FIGURE 2. CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CUTANEOUS T-CELL-LYMPHOMA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CUTANEOUS T-CELL-LYMPHOMA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CUTANEOUS T-CELL-LYMPHOMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CUTANEOUS T-CELL-LYMPHOMA MARKET DYNAMICS
  • TABLE 7. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY MYCOSIS FUNGOIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY SEZARY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY BIOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TOPICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PHOTOTHERAPY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY CHEMOTHERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY TREATMENT DRUGS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CUTANEOUS T-CELL-LYMPHOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. CUTANEOUS T-CELL-LYMPHOMA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 240. CUTANEOUS T-CELL-LYMPHOMA MARKET, FPNV POSITIONING MATRIX, 2023